US Oncologist Survey: Optimizing Treatment for Advanced Non-Hodgkin's Lymphoma

April 2011 | 61 pages | ID: UB0FBA71C17EN
The Assessment Group

Abstracts

Experience real patient situations that progressively unfold, presented to a representative sample of 158 US oncologists who manage 11 or more patients monthly with non-Hodgkin’s lymphoma. Oncologists were presented with four patient case scenarios and asked to respond to open-ended questions concerning their choices of treatment regimens, factors that influenced their decisions, and barriers to optimal patient management. This primary research provides the oncology prescribing information that you are missing, directly from high-prescribing US oncologists on the treatment of specific patient types.

Patient situations:

• Asymptomatic indolent lymphoma
• Elderly infirm patient with advanced follicular lymphoma
• Relapsed large cell lymphoma and
• Large cell lymphoma with compromised cardiac function

Treatment decisions for advanced stages of cancer are difficult to track as information quickly changes along with the introduction of new information and products impacting oncologists’ decisions. This series of reports will allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer.

This report allows you to:

• Understand what occurs with actual patients
• Access the most up-to-date prescribing trends
• Gain actionable data for developing and improving your market strategies
• Pinpoint needs of your target audience
• Focus resources to maximize the effectiveness of your budget
• Understand where your product fits
• Understand where your competitor’s product fits
• Design messages to advance brand performance

Contents

EXECUTIVE SUMMARY

CHAPTER 1: INTRODUCTION

Table 1. Treatment Options in Non-Hodgkin’s Lymphoma

CHAPTER 2: RESPONDENT DEMOGRAPHICS

Table 2. Eligibility Criteria for Survey Participation
Figure 2.1 Gender of Survey Respondents
Figure 2.2 Years since Medical School Graduation
Figure 2.3 Practice Settings
Figure 2.4 Practices in NCI Cancer Centers
Figure 2.5 Geographic Settings
Figure 2.7 Number of Physicians in Practice Groups
Figure 2.6 Survey Respondents by State’s Non-Hodgkin’s Lymphoma Mortality
Figure 2.7 Number of Physicians in Practice Groups
Figure 2.8 Minimal Acceptable Level of Evidence in Determining Treatment Regimen

CHAPTER 3: TREATMENT OF ASYMPTOMATIC INDOLENT LYMPHOMA

Figure 3.1 Initial treatment of asymptomatic indolent lymphoma
Figure 3.2 Treatment goals for this patient
Figure 3.3 Confidence in management of this patient
Figure 3.4 Most important barriers to optimal treatment
Figure 3.5 Treatment upon disease progression
Figure 3.6 Treatment on further disease progression
Figure 3.7 Factors influencing treatment

CHAPTER 4: ELDERLY INFIRM PATIENT WITH ADVANCED FOLLICULAR LYMPHOMA

Figure 4.1 Approach to initial treatment of patient
Figure 4.2 Factors influencing treatment choice
Figure 4.3 Preferred next step
Figure 4.4 Treatment for disease progression
Figure 4.5 Contraindication to Zevalin (ibritumomab) use

CHAPTER 5: PATIENT WITH RELAPSED LARGE CELL LYMPHOMA

Figure 5.1 Barriers to optimal care of large cell lymphoma
Figure 5.2 Confidence in treatment
Figure 5.3 First line treatment approach to patient with large cell lymphoma
Figure 5.4 Factors that influence treatment decision
Figure 5.5 Preferred R-CHOP regimen
Figure 5.6 Next step in management following R-CHOP
Figure 5.7 Treatment for progressing B-cell large cell lymphoma
Figure 5.8 Factors influencing treatment decision
Figure 5.9 Treatment following response then relapse from second-line therapy

CHAPTER 6: PATIENT WITH LARGE CELL LYMPHOMA WITH COMPROMISED CARDIAC FUNCTION

Figure 6.1 Confidence in treatment for large cell lymphoma with compromised cardiac function
Figure 6.2 Treatment approach for large cell lymphoma with compromised cardiac function
Figure 6.3 Factors influencing treatment of large cell lymphoma with compromised cardiac function
Figure 6.4 Further treatment for large cell lymphoma with compromised cardiac function
Figure 6.5 Second-line treatment for large cell lymphoma with compromised cardiac function

CHAPTER 7: SUMMARY

Appendix A: Survey Instrument